Trials Sponsors Conditions Drugs Pricing

Conditions

Carcinoma, Non-Small Cell Lung

Outcome Measures

Primary Outcomes (1)

PFS
PFS was defined as the time from recruitment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.
up to 3 years

Secondary Outcomes (2)

ORR
up to 3 years
Overall survival (OS)
up to 3 years

Study Arms (2)

sequential DEB-BACE and Arotinib and Tirelizumab

EXPERIMENTAL

1. First treatment. Only infusion chemotherapy (THP + Nedaplatin + Letitrexed), THP 20 \~ 30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2. 2. Second treatment. After infusion chemotherapy, Callispheres microspheres is used for embolization: Callispheres microspheres (300-500 μ m) 1tube was loaded and adsorbed THP (40 \~ 600mg/m2) End point of embolization: stagnation of blood flow in tumor feeding artery. 3. The third treatment. Arotinib, 8-12mg, oral (stop oral for 1W every 3W).Tirelizumab, 200mg, intravenous drip (every 3W).

Drug: sequential DEB-BACE and Arotinib and Tirelizumab

DEB-BACE alone

ACTIVE COMPARATOR

Drug: DEB-BACE alone

Interventions

sequential DEB-BACE and Arotinib and TirelizumabDrug

DEB-BACE+Arotinib + Tirelizumab

sequential DEB-BACE and Arotinib and Tirelizumab

DEB-BACE aloneDrug

DEB-BACE alone

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 85 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Has fully understood and voluntarily signed an written Informed Consent and agreed to follow the research plan treatment and visiting plan;
Aged \>=18 years, \<= 85 years;

Sponsors & Collaborators

Gang Wu
Otherlead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Gang Wu, M.D.

CONTACT

+86 13938570175 wuganghenan2015@163.com

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Chief physician

Study Record Dates

First Submitted

May 4, 2022

First Posted

May 18, 2022

Study Start

July 1, 2022

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

December 1, 2022

Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

sequential DEB-BACE and Arotinib and Tirelizumab

DEB-BACE alone

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

sequential DEB-BACE and Arotinib and Tirelizumab

DEB-BACE alone

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record